Drug profile · INN
cephradine
VELOSEF
cephradine (VELOSEF) is a bacterial penicillin-binding protein inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Drug details — cephradine
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 20
- Programs
- 8
- Data quality
- 0.89
Quick answer
cephradine (VELOSEF) is a bacterial penicillin-binding protein inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial penicillin-binding protein inhibitor
Primary target: Bacterial penicillin-binding protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2026093586
COMBINAISON D'UN INHIBITEUR DE L'ALDOSTÉRONE SYNTHASE (ASI) ET D'UN INHIBITEUR DU CO-TRANSPORTEUR SODIUM-GLUCOSE DE TYPE 2 (SGLT2I) DESTINÉE À ÊTRE UTILISÉE DANS DES MÉTHODES VISANT À RÉDUIRE LE RISQUE D'ÉVÉNEMENTS CARDIOVASCULAIRES ET D'INSUFFISANCE CARDIAQUE CHEZ UN SUJET
granted -
US 12383566
Inhibition of SLC transporter activity or expression to attenuate anthracycline-induced cardiotoxicity
granted -
US 12365659
Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers
granted -
US 12350510
Magnetic microwires for energy-transporting biomedical applications
granted -
US 12336835
Neuromodulation to target glucose transporter and/or incretin pathways
granted -
US 12329780
Acute and chronic mitochondrial electron transport chain dysfunction treatments and graphenic materials for use thereof
granted -
US 12291508
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 12247973
Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer
granted -
US 12173306
Codon-optimized reduced-size ATP7A CDNA and uses for treatment of copper transport disorders
granted -
US 12152270
Neurotransmitter transport in probiotics
granted -
US 12060362
Inhibitors of glucose transporters (GLUTs)
granted -
US 12029577
Neuromodulation to target glucose transporter and/or incretin pathways
granted -
US 11986446
Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
granted -
US 11945794
Nuclear transport modulators and uses thereof
granted -
US 11813257
Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
granted -
US 11787771
Hydrazide containing nuclear transport modulators and uses thereof
granted -
US 11666547
Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1)
granted -
US 11639347
Modulators of ATP-binding cassette transporters
granted -
US 11396654
Neutral nanotransporters
granted -
US 11365195
Atypical inhibitors of monoamine transporters; method of making; and use thereof
granted
Frequently asked questions
What is cephradine?
cephradine (VELOSEF) is a bacterial penicillin-binding protein inhibitor. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for cephradine?
VELOSEF is a marketed brand name for cephradine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cephradine?
cephradine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.